Dahal, Lekh N.Basu, NeilYoussef, HazemKhanolkar, Rahul C.Barker, Robert N.Erwig, Lars P.Ward, Frank J.2016-09-092016-09-092016-08-04Dahal, L N, Basu, N, Youssef, H, Khanolkar, R C, Barker, R N, Erwig, L P & Ward, F J 2016, 'Immunoregulatory soluble CTLA-4 modifies effector T cell responses in systemic lupus erythematosus', Arthritis Research & Therapy, vol. 18, 180, pp. 1-11. https://doi.org/10.1186/s13075-016-1075-11478-6354http://hdl.handle.net/2164/7465Acknowledgments This work was supported by Arthritis Research UK (Grant no. 19282). We are grateful to Dr. Nick Fluck for his invaluable support in recruiting patients for the study, and Mrs. Vivien Vaughan for her invaluable expertise in recruiting study participants and maintaining ethical documentation.111255824engSDG 3 - Good Health and Well-beingSoluble CTLA-4Systemic lupus erythematosusImmune regulationR MedicineArthritis Research UK (ARUK)19282RJournal article10.1186/s13075-016-1075-118